Recombinant Factor VIII Combined With Recombinant Von Willebrand Factor In Patients With Severe Hemophilia A: A Prospective Clinical Study Of Safety and Pharmacokinetics

被引：0
|
作者：
Lissitchkov, Toshko
Windyga, Jerzy
Konkle, Barbara A.
Draxler, Wolfgang
Chapman, Miranda
Wong, Wing-Yen
Sorensen, Benny
Ewenstein, Bruce M.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.336.336
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
336
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety, efficacy and pharmacokinetics of a recombinant von willebrand factor in patients with severe von willebrand disease: a prospective clinical trial
    Gill, J.
    Castaman, G.
    Windyga, J.
    Kouides, P.
    Ragni, M.
    Leebeek, F.
    Obermann-Slupetzky, O.
    Chapman, M.
    Fritsch, S.
    Pavlova, B. G.
    Presch, I
    Ewenstein, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 127 - 127
  • [2] Pharmacokinetics of a Recombinant Von Willebrand Factor in Patients with Severe Von Willebrand Disease
    Ragni, Margaret V.
    Castaman, Giancarlo
    Gill, Joan Cox
    Kouides, Peter
    Chapman, Miranda
    Sytkowski, Arthur
    Obermann-Slupetzky, Ortrun
    Presch, Isabella
    Fritsch, Sandor
    Ewenstein, Bruce M.
    BLOOD, 2015, 126 (23)
  • [3] Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A
    Powell, J. S.
    Nugent, D. J.
    Harrison, J. A.
    Soni, A.
    Luk, A.
    Stass, H.
    Gorina, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (02) : 277 - 283
  • [4] Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease
    Gill, Joan C.
    Castaman, Giancarlo
    Windyga, Jerzy
    Kouides, Peter
    Ragni, Margaret
    Leebeek, Frank W. G.
    Obermann-Slupetzky, Ortrun
    Chapman, Miranda
    Fritsch, Sandor
    Pavlova, Borislava G.
    Presch, Isabella
    Ewenstein, Bruce
    BLOOD, 2015, 126 (17) : 2038 - 2046
  • [5] Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats
    Christensen, Isabell Vargas
    Loftager, Mette
    Rode, Frederik
    Nielsen, Hanne Morck
    Kreilgaard, Mads
    Larsen, Malte Selch
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2019, 17 (06) : 964 - 974
  • [6] PHARMACOKINETICS OF MONOCLONALLY-PURIFIED AND RECOMBINANT FACTOR-VIII IN PATIENTS WITH SEVERE VON-WILLEBRAND DISEASE
    MORFINI, M
    MANNUCCI, PM
    TENCONI, PM
    LONGO, G
    MAZZUCCONI, MG
    RODEGHIERO, F
    CIAVARELLA, N
    DEROSA, V
    ARTER, A
    THROMBOSIS AND HAEMOSTASIS, 1993, 70 (02) : 270 - 272
  • [7] Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A
    Zhang, Y.
    Roberts, J.
    Tortorici, M.
    Veldman, A.
    St Ledger, K.
    Feussner, A.
    Sidhu, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (06) : 1106 - 1114
  • [8] Efficacy and Safety of a Recombinant von Willebrand Factor for Bleed Treatment in Patients with Severe von Willebrand Disease
    Gill, J.
    Castaman, G.
    Windyga, J.
    Kouides, P.
    Ragni, M.
    Leebeek, F.
    HAEMOPHILIA, 2015, 21 (03) : E263 - E263
  • [9] EFFICACY AND SAFETY OF RECOMBINANT FACTOR VIII PRODUCTS IN PATIENTS WITH HEMOPHILIA A
    Musso, Robert
    DRUGS OF TODAY, 2008, 44 (10) : 735 - 750
  • [10] Recombinant coagulation factor VIII Fc-von Willebrand factor fusion protein Treatment of hemophilia A
    Villarreal-Martinez, Laura
    Zamora-Martinez, Paola Lizeth
    DRUGS OF THE FUTURE, 2022, 47 (10) : 711 - 714
12345